A rationale for chemoradiation (vs radiotherapy) in salivary gland cancers? On behalf of the REFCOR (French rare head and neck cancer network).
about
Multidisciplinary Management of Salivary Gland Cancers.Adenoid cystic carcinoma: A review of recent advances, molecular targets, and clinical trials.Multi-institutional retrospective study of mucoepidermoid carcinoma treated with carbon-ion radiotherapyThe Present and Future Opportunities of the Rare Cancer Network: An International Consortium for Advancement of Oncologic Care.Overcoming adaptive resistance in mucoepidermoid carcinoma through inhibition of the IKK-β/IκBα/NFκB axisOngoing challenges in the treatment of adenoid cystic carcinoma of the head and neck.The rare cancer network: ongoing studies and future strategy.Aggressive Salivary Malignancies at Early Stage: Outcomes and Implications for Treatment.Outcomes and prognostic factors for surgery followed by modern radiation therapy in parotid gland carcinomas.Targeting histone deacetylase and NFκB signaling as a novel therapy for Mucoepidermoid Carcinomas.Reduced chromatin acetylation of malignant salivary gland tumors correlates with enhanced proliferation.Cytogenetic and immunohistochemical biomarker profiling of therapy-relevant factors in salivary gland carcinomas.FOLFOX activity in a rare case of metastatic colonic adenocarcinoma of the tongue: a case report.Adjuvant radiotherapy versus concurrent chemoradiotherapy for the management of high-risk salivary gland carcinomas.A feasibility and safety study of concurrent chemotherapy based on genetic testing in patients with high-risk salivary gland tumors: Preliminary results.Contemporary Management of Benign and Malignant Parotid Tumors.
P2860
Q30248325-9679C7C7-F102-447B-BBA6-B34DC49A153DQ30301145-6C6879E8-CA9C-4B46-8918-2A6958976FBBQ33873306-751A5E4E-E307-4701-B061-E3C837E83B30Q36146505-2C85FB2D-5A17-4B42-92D8-44A77F7854E9Q37687338-4E97A6A5-13E9-473F-8C68-7ABE7E8E10CCQ38430357-0340E146-6405-4527-B9B7-C00AB2DD526DQ39119889-FB9B6092-984C-4B3E-B4C2-BD2D75A4CCCDQ39285563-F8DE4289-64B3-4D0A-B72C-72485C75B62CQ40693954-33B25122-D06C-4ADB-85CA-738EA9F47E3CQ48120446-B54AA149-E2D5-471A-92FB-9E47F55471D5Q48276258-069CA541-505F-4A69-8AFD-574378E83F04Q50675747-00F6A42E-AA77-435A-A6DC-B28EF38F2F14Q52560689-51A3458A-E903-4687-89A3-922EBC12A785Q53769670-AD4B7692-D454-4EC2-955C-82AA140923D4Q55129591-E138533D-9AB4-4945-A36A-FCDFD7D2D738Q55378954-C24B5016-3C96-4570-8F49-1447AE8765A9
P2860
A rationale for chemoradiation (vs radiotherapy) in salivary gland cancers? On behalf of the REFCOR (French rare head and neck cancer network).
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
A rationale for chemoradiation ...... head and neck cancer network).
@en
type
label
A rationale for chemoradiation ...... head and neck cancer network).
@en
prefLabel
A rationale for chemoradiation ...... head and neck cancer network).
@en
P2093
P1476
A rationale for chemoradiation ...... head and neck cancer network).
@en
P2093
Ali Mohamed Ali
Anne-Catherine Baglin
Emile Reyt
Francois Janot
Pierre-Yves Marcy
Stéphane Vignot
Sylvie Testelin
Thomas Cerda
Xu Shan Sun
P304
P356
10.1016/J.CRITREVONC.2014.02.002
P577
2014-02-16T00:00:00Z